RxDoctor Payments Data

Jonathan Jones, MD

Family Medicine · Dyer, INNPI 1043740418

Payments from drug & device makers

$9,438in general payments, 2019–2025

Across 592 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$909
  • AstraZeneca$900
  • Pfizer$872
  • Amgen$796
  • Ironwood Pharmaceuticals, Inc$512
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$9,438100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,438 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$209,485
Medicare patients
406
Services billed
4,520

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide58$67,090
FarxigaDapagliflozin Propanediol51$44,161
ZenpepLipase/Protease/Amylase17$42,247
JardianceEmpagliflozin30$38,612
EliquisApixaban35$37,525
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$36,777
LinzessLinaclotide22$31,096
MounjaroTirzepatide25$28,307
RybelsusSemaglutide25$27,232
TrulicityDulaglutide17$17,829
EntrestoSacubitril/Valsartan21$16,840
JanuviaSitagliptin Phosphate20$11,256
Breo ElliptaFluticasone/Vilanterol23$9,945
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$7,843
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$5,959

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$909$94,32283 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$273$54,56685 claims
AstraZenecaFarxiga, Breztri Aerosphere$900$50,12063 claims
Lilly USA, LLCMounjaro, Trulicity$389$46,13542 claims
PfizerEliquis, Paxlovid$872$38,98046 claims
Boehringer IngelheimJardiance$325$38,61230 claims
AbbVieLinzess, Synthroid$1,628$33,35858 claims
NovartisEntresto$130$16,84021 claims
MerckJanuvia$162$11,25620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Dyer

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →